EMA Authorised: Inlyta (axitinib) — Pfizer Europe MA EEIG

View source ↗

Summary

EU authorisation granted for Inlyta (axitinib) for renal cell carcinoma. The marketing authorisation holder is Pfizer Europe MA EEIG.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• INLYTA (AXITINIB)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Renal Cell. MAH: Pfizer Europe MA EEIG. Decision date: 21/01/2025